---

---

tags : Disease    entities : Beam therapeutics inc.   

save search

---

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Published: 2023-10-31 (Crawled : 10:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 32.07% | O: -0.03% H: 0.0% C: 0.0%
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| 34.48% | O: 7.69% H: 7.3% C: 2.72%
disease acquire cardiovascular agreement

---

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
Published: 2023-10-25 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| 31.59% | O: -1.33% H: 1.82% C: 0.36%
beam-301 disease durability preclinical therapeutics

---

Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial
Published: 2023-05-25 (Crawled : 12:00) - prnewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -23.01% | O: -0.54% H: 0.3% C: -2.98%
disease cell medical trial therapeutics

---

Sickle Cell Disease Market to Observe Impressive Growth, Predicts DelveInsight | Key Companies Active in the Domain - Sanofi, Novartis, Vertex, CRISPR, Vifor, Pfizer, GlaxoSmithKline, Alexion, Global Blood
Published: 2023-05-22 (Crawled : 15:00) - prnewswire.com
VRTX | News | $393.51 0.1% 0.1% 950K |

Health Technology

| 15.59% | O: 0.69% H: 0.56% C: -1.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -16.89% | O: -0.75% H: 0.0% C: 0.0%
EDIT | $5.56 -0.89% -0.9% 1.7M |

Health Technology

| -40.45% | O: -0.97% H: 4.98% C: 4.44%
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -25.59% | O: 0.2% H: 2.51% C: 1.56%
AGIO | News | $29.43 1.38% 1.36% 550K |

Health Technology

| 11.69% | O: 0.38% H: 2.48% C: 1.87%
disease companies active cell blood global market

---

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| Email alert Add to watchlist
disease preclinical therapeutics platform

---

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -41.06% | O: -2.27% H: 6.76% C: 3.29%
disease preclinical meeting therapeutics

---

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection
Published: 2022-09-19 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -54.21% | O: -1.51% H: 0.78% C: -2.68%
hepatitis disease therapeutics potential infection chronic hepatitis b

---

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Published: 2022-06-27 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -39.54% | O: 0.71% H: 2.94% C: 0.65%
research disease therapeutics

---

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
Published: 2022-03-25 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -56.2% | O: -0.02% H: 2.4% C: -1.09%
rare genomic conference therapeutics disease

---

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Published: 2022-01-10 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M |

Health Technology

| -54.11% | O: 0.63% H: 0.0% C: 0.0%
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -62.22% | O: 3.65% H: 0.77% C: -2.89%
disease rare

---

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| Email alert Add to watchlist
therapeutics disease preclinical pre-clinical

---

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation
Published: 2021-10-19 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -71.67% | O: 2.35% H: 3.8% C: 1.63%
disease preclinical pre-clinical

---

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection
Published: 2021-09-27 (Crawled : 11:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -73.61% | O: -3.2% H: 1.81% C: 0.59%
disease hepatitis potential injection preclinical pre-clinical infections chronic hepatitis b

---

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| -80.03% | O: 0.58% H: 5.66% C: 3.2%
APLS | $47.51 -1.08% -1.09% 1.9M |

Health Technology

| -24.83% | O: 1.27% H: 7.16% C: 5.94%
disease collaboration research therapy

---

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
Published: 2020-12-05 (Crawled : 12:00) - globenewswire.com
BEAM | $24.33 0.08% 0.08% 1.7M |

Health Technology

| Email alert Add to watchlist
disease

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---